Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

relapse

  • Home
  • relapse
Early High-Resolution Immune Profiles Are Linked to Survival and Relapse After Allogeneic Stem Cell Transplantation
Posted inHematology-Oncology news Pathology & Lab Medicine/Bệnh học

Early High-Resolution Immune Profiles Are Linked to Survival and Relapse After Allogeneic Stem Cell Transplantation

Posted by MedXY By MedXY 06/02/2026
Early immune profiling after allogeneic stem cell transplant was linked to survival and relapse risk. Stronger innate and adaptive immune recovery predicted better outcomes, while certain activation and checkpoint markers were associated with worse survival.
Read More
Cellular and Molecular Mechanisms of Relapse After CD19/CD22 Dual-Target CAR T-Cell Therapy in B-Cell Acute Lymphoblastic Leukemia
Posted inHematology-Oncology news

Cellular and Molecular Mechanisms of Relapse After CD19/CD22 Dual-Target CAR T-Cell Therapy in B-Cell Acute Lymphoblastic Leukemia

Posted by MedXY By MedXY 06/02/2026
A study of 91 B-ALL patients found that relapse after CD19/CD22 dual-target CAR T-cell therapy is mainly driven by CAR T-cell functional failure and antigen loss, with PAX5 mutations linked to early immune escape.
Read More
Defining Relapse in Schizophrenia: New International Consensus to Standardize Research and Care
Posted innews Psychiatry

Defining Relapse in Schizophrenia: New International Consensus to Standardize Research and Care

Posted by MedXY By MedXY 10/30/2025
An international expert consensus offers standardized, operational criteria for defining relapse in schizophrenia to reduce study heterogeneity, improve research comparability, and guide clinical reporting.
Read More
Comparative Effectiveness of Long-Acting Injectable Versus Oral Antipsychotics in Older Adults with Schizophrenia: Insights from Hong Kong’s Population-Based Study
Posted inInternal Medicine Psychiatry Specialties

Comparative Effectiveness of Long-Acting Injectable Versus Oral Antipsychotics in Older Adults with Schizophrenia: Insights from Hong Kong’s Population-Based Study

Posted by MedXY By MedXY 10/18/2025
This study compares long-acting injectable to oral antipsychotics in older schizophrenia patients, highlighting benefits in relapse prevention and mortality reduction, with specific considerations for adverse effects.
Read More
Balancing Risks and Benefits: Early Antipsychotic Dose Reduction Versus Maintenance After First-Episode Psychosis Remission
Posted inClinical Updates news Psychiatry Specialties

Balancing Risks and Benefits: Early Antipsychotic Dose Reduction Versus Maintenance After First-Episode Psychosis Remission

Posted by MedXY By MedXY 10/01/2025
A randomized clinical trial reveals early dose reduction of antipsychotics after first-episode psychosis remission increases short-term relapse risk and lowers quality of life, but may improve long-term functioning over four years.
Read More
  • Optimizing Smoking Cessation Interventions in Lung Cancer Screening: Insights from the CASTL Trial
  • Shared Genetic Foundations of Idiopathic Pulmonary Fibrosis in East Asian and European Populations
  • Synergistic Impact of Clonal Hematopoiesis and Genetic Predisposition on Age-Related Macular Degeneration Risk: Insights from a Large UK Biobank Cohort
  • Comparing Long-Term Systemic Risks of Biologic Versus Conventional Therapy in Non-Infectious Uveitis
  • Nicotinamide Supplementation and Primary Open-Angle Glaucoma in Patients With Ocular Hypertension: Evidence, Mechanisms, and Clinical Implications
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prostate cancer public health quality of life randomized clinical trial randomized controlled trial randomized trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in